How to Order KENGREAL® (cangrelor)

Wholesaler ordering information and storage guidelines


Supplied as a sterile lyophilized powder in single-use 10 mL vials, each containing 50 mg of KENGREAL.

NDC 10122-620-10NDC No.L x W x H: 5.9 x 2.5 x 2.5 inCarton dimensionsCarton weight5.9 oz10 count of10 mL vialscontaining50 mg ofKENGREAL
  • NDC 10122-620-01: 10 mL vial containing 50 mg of KENGREAL
Image of KENGREAL Order Sheet

Get additional ordering details

Download the Order Sheet now

Please use standard ordering procedure through your wholesaler by referencing the following:

10183655ABCWholesalerBox of 10 vials50 mg/10 mL56961173745882216358HD SmithMcKessonMorris & DicksonCardinal5412200Wholesaleritem numbersfor box of10 vials

If the product is not available at your wholesaler, your wholesaler can easily coordinate a drop shipment via Next-Day Saver from a Chiesi USA distribution provider.

Storing and handling KENGREAL

KENGREAL vials should be stored at USP Controlled Room Temperature [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted].1

Need help?

For additional assistance or questions not answered on this website, contact Chiesi USA, Inc. Customer Service at 1-855-483-3989.

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.


KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Reference: 1. KENGREAL® (cangrelor) Prescribing Information. 2016.